U.S. Physical Therapy Past Earnings Performance

Past criteria checks 0/6

U.S. Physical Therapy's earnings have been declining at an average annual rate of -9.9%, while the Healthcare industry saw earnings growing at 10.6% annually. Revenues have been growing at an average rate of 8% per year. U.S. Physical Therapy's return on equity is 4.7%, and it has net margins of 2.2%.

Key information

-9.9%

Earnings growth rate

-11.8%

EPS growth rate

Healthcare Industry Growth	15.7%
Revenue growth rate	8.0%
Return on equity	4.7%
Net Margin	2.2%
Last Earnings Update	30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How U.S. Physical Therapy makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

DB:UPH Revenue, expenses and earnings (USD Millions)
Date	Revenue	Earnings	G+A Expenses
30 Sep 24	639	14	57
30 Jun 24	621	16	54
31 Mar 24	606	18	52
31 Dec 23	599	18	52
30 Sep 23	585	24	50
30 Jun 23	575	26	50
31 Mar 23	564	28	48
31 Dec 22	548	29	46
30 Sep 22	536	39	45
30 Jun 22	522	38	46
31 Mar 22	509	37	47
31 Dec 21	490	31	47
30 Sep 21	477	31	47
30 Jun 21	461	30	44
31 Mar 21	418	32	41
31 Dec 20	418	32	42
30 Sep 20	423	30	43
30 Jun 20	431	31	43
31 Mar 20	473	29	45
31 Dec 19	477	31	45
30 Sep 19	472	30	44
30 Jun 19	468	23	44
31 Mar 19	457	18	42
31 Dec 18	449	17	41
30 Sep 18	442	18	41
30 Jun 18	432	22	39
31 Mar 18	421	21	38
31 Dec 17	410	22	36
30 Sep 17	392	20	34
30 Jun 17	377	20	33
31 Mar 17	363	21	32
31 Dec 16	353	21	32
30 Sep 16	348	20	34
30 Jun 16	344	21	33
31 Mar 16	337	21	32
31 Dec 15	327	21	31
30 Sep 15	320	21	30
30 Jun 15	313	20	31
31 Mar 15	308	20	31
31 Dec 14	301	19	30
30 Sep 14	290	19	29
30 Jun 14	278	18	28
31 Mar 14	267	18	27

Quality Earnings: UPH has a large one-off loss of $28.5M impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: UPH's current net profit margins (2.2%) are lower than last year (4.1%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: UPH's earnings have declined by 9.9% per year over the past 5 years.

Accelerating Growth: UPH's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: UPH had negative earnings growth (-40.6%) over the past year, making it difficult to compare to the Healthcare industry average (36.2%).

Return on Equity

High ROE: UPH's Return on Equity (4.7%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/05 16:09
End of Day Share Price	2025/01/03 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

U.S. Physical Therapy, Inc. is covered by 16 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Michael Petusky	Barrington Research Associates, Inc.
Alexander Paris	Barrington Research Associates, Inc.
Joanna Sylvia Gajuk	BofA Global Research

U.S. Physical Therapy Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

Third quarter 2024 earnings released: EPS: US$0.39 (vs US$0.51 in 3Q 2023)

U.S. Physical Therapy, Inc. to Report Q3, 2024 Results on Nov 05, 2024

U.S. Physical Therapy, Inc. to Report Q2, 2024 Results on Aug 13, 2024

First quarter 2024 earnings released: EPS: US$0.54 (vs US$0.58 in 1Q 2023)

Full year 2023 earnings released: EPS: US$1.99 (vs US$2.25 in FY 2022)

U.S. Physical Therapy, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Recent updates

President & COO recently sold €179k worth of stock

Third quarter dividend of US$0.44 announced

Third quarter 2024 earnings released: EPS: US$0.39 (vs US$0.51 in 3Q 2023)

U.S. Physical Therapy, Inc. Declares Quarterly Dividend, Payable on December 6, 2024

U.S. Physical Therapy, Inc. to Report Q3, 2024 Results on Nov 05, 2024

U.S. Physical Therapy, Inc. Declares Quarterly Dividend, Payable on September 13, 2024

U.S. Physical Therapy, Inc. announced delayed 10-Q filing

U.S. Physical Therapy, Inc. to Report Q2, 2024 Results on Aug 13, 2024

Now 21% undervalued after recent price drop

Chairman & CEO recently sold €196k worth of stock

Chief Operating Officer - East recently sold €242k worth of stock

First quarter dividend of US$0.44 announced

First quarter 2024 earnings released: EPS: US$0.54 (vs US$0.58 in 1Q 2023)

U.S. Physical Therapy, Inc., Annual General Meeting, May 21, 2024

Chief Operating Officer - West recently sold €253k worth of stock

Fourth quarter dividend of US$0.44 announced

New minor risk - Profit margin trend

U.S. Physical Therapy, Inc. Increases Quarterly Dividend, Payable on April 5, 2024

New minor risk - Earnings quality

Full year 2023 earnings released: EPS: US$1.99 (vs US$2.25 in FY 2022)

Now 21% undervalued

U.S. Physical Therapy, Inc. to Report Q4, 2023 Results on Feb 28, 2024

U.S. Physical Therapy, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Now 21% undervalued after recent price drop

Third quarter 2023 earnings released: EPS: US$0.62 (vs US$0.72 in 3Q 2022)

U.S. Physical Therapy, Inc. Declares Quarterly Dividend, Payable on December 8, 2023

U.S. Physical Therapy, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Chief Operating Officer - West recently sold €413k worth of stock

Second quarter 2023 earnings released: EPS: US$0.80 (vs US$0.87 in 2Q 2022)

U.S. Physical Therapy, Inc. Declares Quarterly Dividend, Payable on September 8, 2023

U.S. Physical Therapy, Inc. (NYSE:USPH) acquired a 70% stake in U.S. Physical Therapy, Inc. (NYSE:USPH) for $2.1 million.

U.S. Physical Therapy, Inc. to Report Q2, 2023 Results on Aug 08, 2023

U.S. Physical Therapy, Inc. (NYSE:USPH) acquired 75% interest in Physical therapy practice with four clinics for $3.1 million

U.S. Physical Therapy, Inc. has completed a Follow-on Equity Offering in the amount of $150.00003 million.

U.S. Physical Therapy, Inc. Elects Nancy Ham to the Board of Directors

Upcoming dividend of US$0.43 per share at 1.6% yield

U.S. Physical Therapy Declares Quarterly Dividend, Payable on June 9, 2023

First quarter 2023 earnings released: EPS: US$0.57 (vs US$0.67 in 1Q 2022)

Independent Director recently sold €439k worth of stock

Executive VP recently sold €87k worth of stock

Upcoming dividend of US$0.43 per share at 1.7% yield

Full year 2022 earnings released: EPS: US$2.25 (vs US$2.42 in FY 2021)

U.S. Physical Therapy, Inc. to Report Q4, 2022 Results on Feb 22, 2023

Independent Director recently sold €573k worth of stock

President recently sold €858k worth of stock

U.S. Physical Therapy, Inc. (NYSE:USPH) acquired 80% stake in Thirteen-clinic physical therapy practice from practice’s owners for $25 million.

U.S. Physical Therapy, Inc. (NYSE:USPH) acquired 80% stake in Thirteen-clinic physical therapy practice for $25 million.

Insufficient new directors

Upcoming dividend of US$0.41 per share

Chief Operating Officer - West recently sold €162k worth of stock

Now 23% undervalued after recent price drop

Third quarter 2022 earnings released: EPS: US$0.73 (vs US$0.66 in 3Q 2021)

U.S. Physical Therapy, Inc. Provides Operating Guidance for 2022

U.S. Physical Therapy, Inc. (NYSE : USPH) acquired 60% stake in Fourteen-clinic physical therapy practice for $19.3 million.

U.S. Physical Therapy, Inc. to Report Q3, 2022 Results on Nov 03, 2022

U.S. Physical Therapy, Inc. (NYSE:USPH) acquired 80% stake in Two-Clinic Physical Therapy Practice for $4.2 million.

Director recently bought €78k worth of stock

U.S. Physical Therapy, Inc. (NYSE:USPH) acquired a 70% stake in six-clinic physical therapy practice in West Virginia and Pennsylvania for $3.5 million.

Independent Director recently bought €82k worth of stock

Independent Director recently bought €54k worth of stock

Second quarter 2022 earnings released: EPS: US$0.86 (vs US$0.82 in 2Q 2021)

U.S. Physical Therapy, Inc. Declares Quarterly Dividend, Payable on September 16, 2022

U.S. Physical Therapy, Inc. to Report Q2, 2022 Results on Aug 04, 2022

First quarter 2022 earnings released: EPS: US$0.68 (vs US$0.21 in 1Q 2021)

U.S. Physical Therapy, Inc. Declares Quarterly Dividend, Payable on June 14, 2022

Insufficient new directors

U.S. Physical Therapy, Inc. to Report Q1, 2022 Results on May 05, 2022

U.S. Physical Therapy, Inc., Annual General Meeting, May 17, 2022

U.S. Physical Therapy, Inc. (NYSE:USPH) acquired a 70% stake in Madden and Gilbert Physical Therapy, LP from Chad Madden, Michael Gilbert and others for $11.5 million.